Ren et al. showed that TEAD4 expression not only has a higher diagnostic value with better sensitivity and lower false positive rate than TEAD1-3 in ovarian serous carcinoma patients, but also negatively correlates with the tumor-infiltrating immune cells (Ren et al., 2021). Here, TEAD1 is linked to neoplasm.